Pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 90% of all
pancreatic tumours, is a devastating malignancy with an extremely poor prognosis, as …

Pancreatic ductal adenocarcinoma (PDAC) occurs mainly in people older than 50 years of
age. Although great strides have been taken in treating PDAC over the past decades its …

Combined radiochemotherapy is the currently used therapy for locally advanced pancreatic
ductal adenocarcinoma (PDAC), but normal tissue toxicity limits its application. Here we test …

Background Multiple trials have demonstrated a survival benefit for adjuvant chemotherapy
after resection of pancreatic adenocarcinoma. This study aimed to identify the rate for …

Currently, pancreatic adenocarcinoma mainly occurs after 60 years of age, and its prognosis
remains poor despite modest improvements in recent decades. The aging of the population …

Syngeneic, immunocompetent allograft tumor models recapitulate important aspects of the
tumor microenvironment and have short tumor latency with predictable growth kinetics …

Since its initial characterization, pancreatic ductal adenocarcinoma has remained one of the
most devastating and difficult cancers to treat. Pancreatic cancer is the fourth leading cause …

Background Recent papers consider surgery as an option for synchronous liver
oligometastatic patients [metastatic pancreatic ductal adenocarcinoma (mPDAC)]. In this …

Two areas that remain the focus of improvement in pancreatic cancer include high post-
operative morbidity and inability to uniformly translate surgical success into long-term …

Non-metastatic pancreatic adenocarcinoma (PDAC) is associated with a high rate of
recurrence and lethality. In addition, less than half of all patients are able to complete …